olivLaw · US equity research
Immatics N.V. IMTX
Biological Products, (No Diagnostic Substances) · SIC 2836 · Vertical: Biological Products, (No Diagnostic Substances) (SIC 2836)
Immatics N.V. is a clinical-stage biopharmaceutical company focused on PRAME-directed immunotherapies for more than 50 cancers. It is preparing its first product, anzu-cel, for advanced melanoma in the U.S., with a launch planned for the second half of 2027 if approval is obtained, while collaboration revenue fell in fiscal 2025 and the net loss reached 196,447 thousand EUR.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, Immatics N.V. (IMTX) stock was 6.91 USD (−2.33% on the day), with beta 1.37, 52-week range 6.73–11.87 USD. Latest reported quarter (Q4 2024): net income of 40.8 m USD, diluted EPS 0.38 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 37.0
- weak (30–45)
- Bollinger (20, 2)
- 6.73 – 7.68
- in the lower half of the band · %B 0.19 · band width 13.2%
- SMA 50 / 200
- 8.13 / 9.55
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.27 / -0.30
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −10.6% | −1.1% | −9.5 pp | — |
| 3 months | −29.3% | −0.5% | −28.8 pp | — |
| 6 months | −40.0% | +4.4% | −44.4 pp | — |
| Year to date | −34.2% | +12.3% | −46.5 pp | — |
| 1 year | −25.3% | +13.5% | −38.8 pp | +8.1% |
| 3 years | −28.1% | +76.4% | −104.5 pp | +3.1% |
| 5 years | −44.7% | +63.7% | −108.4 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q4 2024 · 31 Dec 2024
Quarterly statements · EUR
| Fiscal year | Q1 '20 | Q2 '20 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 |
|---|---|---|---|---|---|---|
| Pre-tax income | — | — | -1.7 m | -17.9 m | -2.4 m | 43.3 m |
| Net income | — | — | -2.2 m | -18.0 m | -5.3 m | 40.8 m |
| Diluted EPS | — | — | -0.03 | -0.17 | -0.08 | 0.38 ≈ |
| Operating cash flow | -11.5 m | -16.3 m ≈ | -32.6 m | -33.2 m ≈ | -33.7 m ≈ | -58.5 m |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
the price (USD) and the reports are in different currencies
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Revenue YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Net income | -31.4 m | -31.6 m | -211.3 m | -93.3 m | 27.7 m | -94.6 m | 15.2 m | -196.4 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | −441.7% | unavailable | −1,390.9% |
| Diluted EPS | unavailable | unavailable | -4.40 | -1.48 | 0.40 | -1.18 | 0.14 | -1.61 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | −395.0% | unavailable | −1,250.0% |
| net % | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Free cash flow | 20.3 m | 68.8 m | -88.1 m | -89.9 m | 94.4 m | -12.6 m | -174.3 m | -183.2 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 345.9 m EUR
- Financial debt
- unavailable EUR
- Net debt
- unavailable EUR
- Equity
- 484.1 m EUR
- Total assets
- 562.3 m EUR
- Debt / equity
- unavailable
- Current ratio
- 11.72x
- ROE
- -37.1%
- ROA
- -31.2%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (EUR)
Income statement · EUR
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Research & development | 67.1 m | 87.6 m | 106.8 m | 118.7 m | 148.1 m | 183.8 m | SEC (XBRL)· 05 Mar 2026verified |
| Operating income | -69.7 m | -86.3 m | 30.0 m | -101.7 m | -38.6 m | -182.0 m | SEC (XBRL)· 05 Mar 2026verified |
| Interest expense | 10.1 m | -1.7 m | 8.3 m | 7.0 m | 1.3 m | 36.7 m | SEC (XBRL)· 05 Mar 2026verified |
| Pre-tax income | -211.8 m | -93.3 m | 42.0 m | -97.0 m | 21.3 m | -198.4 m | SEC (XBRL)· 05 Mar 2026verified |
| Net income | -211.3 m | -93.3 m | 27.7 m | -94.6 m | 15.2 m | -196.4 m | SEC (XBRL)· 05 Mar 2026verified |
| Diluted EPS | -4.40 | -1.48 | 0.40 | -1.18 | 0.14 | -1.61 | SEC (XBRL)· 05 Mar 2026verified |
| Weighted average diluted shares | 48.0 m | 62.9 m | 68.8 m | 80.5 m | 106.8 m | 122.3 m | SEC (XBRL)· 05 Mar 2026verified |
Balance sheet · EUR
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 207.5 m | 133.0 m | 148.5 m | 218.5 m | 236.7 m | 345.9 m | SEC (XBRL)· 05 Mar 2026verified |
| Current assets | 239.0 m | 152.2 m | 377.2 m | 449.4 m | 629.6 m | 504.0 m | SEC (XBRL)· 05 Mar 2026verified |
| Property, plant & equipment, net | 7.9 m | 10.5 m | 13.5 m | 43.7 m | 50.4 m | 42.1 m | SEC (XBRL)· 05 Mar 2026verified |
| Intangibles (excl. goodwill) | 914.0 k | 1.3 m | 1.6 m | 1.5 m | 1.6 m | 1.6 m | SEC (XBRL)· 05 Mar 2026verified |
| Total assets | 254.6 m | 174.6 m | 407.8 m | 510.0 m | 696.1 m | 562.3 m | SEC (XBRL)· 05 Mar 2026verified |
| Current liabilities | 77.5 m | 95.1 m | 106.5 m | 156.6 m | 68.0 m | 43.0 m | SEC (XBRL)· 05 Mar 2026verified |
| Total liabilities | 167.3 m | — | 204.5 m | 292.3 m | — | — | SEC (XBRL)· 27 Mar 2025verified |
| Equity | 87.4 m | 24.1 m | 203.4 m | 217.6 m | 574.8 m | 484.1 m | SEC (XBRL)· 05 Mar 2026verified |
| Shares outstanding at year end | 62.9 m | 62.9 m | 76.7 m | 84.7 m | 121.6 m | 134.1 m | SEC (XBRL)· 05 Mar 2026verified |
Cash flow · EUR
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -80.7 m | -84.7 m | 100.1 m | 18.2 m | -158.0 m | -176.6 m | SEC (XBRL)· 05 Mar 2026verified |
| Capex | 7.4 m | 5.1 m | 5.7 m | 30.8 m | 16.3 m | 6.6 m | SEC (XBRL)· 05 Mar 2026verified |
| Free cash flow | -88.1 m ≈ | -89.9 m ≈ | 94.4 m ≈ | -12.6 m ≈ | -174.3 m ≈ | -183.2 m ≈ | SEC (XBRL)· 05 Mar 2026derived |
| Investing cash flow | -15.9 m | 7.5 m | -209.8 m | -31.4 m | -152.4 m | 204.8 m | SEC (XBRL)· 05 Mar 2026verified |
| Financing cash flow | 207.9 m | -2.6 m | 123.7 m | 84.5 m | 319.7 m | 97.4 m | SEC (XBRL)· 05 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 2 of at least 6
- score weight coverage: 10.4% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: unavailable
Price and reporting are in different currencies; market indicators are unavailable.
Key indicators
Coverage and freshness
Score by group
10% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 3.0%
- Equity risk premium
- 5.5%
- Beta (default)
- 1.00
- Cost of equity
- 8.5%
- Terminal growth
- 2.0%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 2 of at least 6; score weight coverage: 10.4% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | unavailable | unavailable | — |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -5.0x | 0 (on a fixed band) | 60% |
| Current ratio · Balance sheet | 11.7x | 100 (on a fixed band) | 40% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet40/100 · 2/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partialunavailable · 0/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Immatics N.V. (IMTX). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: ROE -37.1%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 2 of at least 6; score weight coverage: 10.4% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 11.7x
What contradicts it
- Interest coverage: -5.0x
Not assessed (insufficient data or a ratio without meaning): ROIC, Net margin, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Biological Products, (No Diagnostic Substances) (SIC 2836) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| AMGNAmgen Inc. | 258.8 bn | 27.7 | 78.4% | 24.1% | +10.0% | +39% / +77% |
| GILDGilead Sciences, Inc. | 216.4 bn | — | -22.3% | -12.5% | +2.4% | +39% / +128% |
| MRNAModerna, Inc. | 103.2 bn | — | -39.0% | -141.4% | −39.9% | +895% / +233% |
| ARGXArgenx Se | 57.6 bn | 47.6 | 20.2% | — | +254.4% | +2% / +107% |
| RVMDRevolution Medicines, Inc. | 43.2 bn | — | -93.6% | -946.8% | unavailable | +157% / +756% |
| BIIBBiogen Inc. | 37.6 bn | 108.8 | 1.9% | 3.4% | +2.2% | +40% / +9% |
| EXELExelixis, Inc. | 17.8 bn | 21.7 | 44.3% | 35.5% | +7.0% | +65% / +234% |
| TECHBio-Techne Corp | 11.4 bn | 62.7 | 9.0% | 15.0% | −0.4% | +13% / +16% |
| QGENQiagen N.V. | 11.0 bn | 26.2 | 11.6% | 20.3% | +5.7% | +6% / +20% |
| IBRXImmunitybio, Inc. | 9.5 bn | — | — | -598.6% | +668.3% | +278% / +143% |
| BEAMBeam Therapeutics Inc. | 2.9 bn | — | -11.3% | -73.9% | +120.0% | +10% / −1% |
| RXRXRecursion Pharmaceuticals, Inc. | 2.4 bn | — | -48.7% | -697.1% | +26.9% | −16% / −43% |
| NVAXNovavax Inc | 1.8 bn | — | — | -59.9% | +64.7% | +51% / +94% |
| TSHATaysha Gene Therapies, Inc. | 1.4 bn | — | -47.1% | -2,728.0% | +17.3% | −8% / +148% |
| INBXInhibrx Biosciences, Inc. | 1.3 bn | — | -1,773.6% | — | +550.0% | +3% / unavailable |
| EVAXEvaxion A | 1.2 bn | — | -100.2% | -102.4% | +125.1% | −50% / −93% |
| GLUEMonte Rosa Therapeutics, Inc. | 923.1 m | — | -42.7% | -560.9% | +63.5% | −33% / +249% |
| PRMEPrime Medicine, Inc. | 901.4 m | — | -373.3% | -4,056.4% | +55.3% | +30% / −32% |
| SLDBSolid Biosciences Inc. | 727.7 m | — | -76.9% | — | −40.6% | +20% / +131% |
| CCCCC4 Therapeutics, Inc. | 383.8 m | — | -48.1% | -289.4% | +1.0% | +15% / +91% |
| AUTLAutolus Therapeutics plc | 367.3 m | — | -133.0% | -238.7% | +644.9% | −2% / −68% |
| AGENAgenus Inc | 313.8 m | 2.6 | — | 69.3% | +10.4% | +53% / −55% |
| SABSSab Biotherapeutics, Inc. | 289.3 m | — | -11.3% | — | −100.0% | −19% / −67% |
| FATEFate Therapeutics Inc | 250.4 m | — | -60.7% | -1,941.1% | −51.2% | +83% / −16% |
| DTILPrecision Biosciences Inc | 226.8 m | — | -112.7% | -85.6% | −50.1% | +49% / −24% |
1- and 3-year price returns: for IMTX from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 05 Mar 2026; since then the company filed 6-K (26 Oct 2026), 6-K (23 Oct 2026), 6-K (26 Aug 2026), 6-K (18 Aug 2026), 6-K (18 Jun 2026), 6-K (02 Jun 2026).
In brief
Immatics N.V. is a clinical-stage biopharmaceutical company focused on PRAME-directed immunotherapies for more than 50 cancers. It is preparing its first product, anzu-cel, for advanced melanoma in the U.S., with a launch planned for the second half of 2027 if approval is obtained, while collaboration revenue fell in fiscal 2025 and the net loss reached 196,447 thousand EUR 1.
SWOT
Strengths
- Leading position in PRAME targeting, with the broadest set of indications and modalities in the field, supported by a proprietary scientific platform 1.
- In-house manufacturing and a proprietary GMP facility that allow a short turnaround time and greater process control 1.
- Collaborations with major partners that bring upfront and potential milestone payments without direct dilution 1.
Weaknesses
- Recurring operating losses and no product sales revenue, which make profitability difficult to reach 1.
- Dependence on external capital and market conditions, with additional funding possibly dilutive or restrictive 1.
- High costs of clinical trials and patient-specific manufacturing, which could exceed initial estimates 1.
Opportunities
Risks
- Persistent operating losseshigh
The company does not expect meaningful commercial revenue for several years and may never achieve profitability 1.
- Need for additional capitalhigh
Without a committed external source of funds, financing could be obtained on unfavorable terms, diluting existing shareholders 1.
- Clinical trial riskshigh
Failure, delay or suspension of clinical trials could change approval timelines and program costs 1.
- Reliance on third parties for manufacturingmedium
Production of product candidates depends on external suppliers, which could affect product quality or availability 1.
- Currency exposurelow
Euro fluctuations against the U.S. dollar could affect reported financial results 1.
Investment thesis
What would need to be true (bull case)
- If anzu-cel obtains approval in the U.S., the company could become the first PRAME product on the market, with a broad portfolio covering several cancer types 1.
- The confirmed response rate reported in the phase 1b trial could support a competitive position in advanced melanoma 1.
- Collaborations with large partners could bring payments and milestones that ease pressure on equity capital 1.
What would break the thesis
- The company has no approved product, and collaboration revenue fell in fiscal 2025, which could prolong the period of losses 1.
- Funding needs could lead to share issuance or loans with restrictive terms, affecting existing shareholders 1.
- Phase 3 studies and regulation could delay the launch, while competition could reach the market earlier 1.
What to watch
- Submission of the anzu-cel Biologics License Application1H 2027
- Interim and final results of the SUPRAME phase 3 trial2026
- Data update for IMA402 and determination of the RP2D dose2H 2026
- Trend in collaboration revenue and milestone paymentsnext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 05 Mar 2026; since then the company filed 6-K (26 Oct 2026), 6-K (23 Oct 2026), 6-K (26 Aug 2026), 6-K (18 Aug 2026), 6-K (18 Jun 2026), 6-K (02 Jun 2026).
The business
Immatics N.V. is a Dutch company headquartered in Amsterdam, with operating offices in Tübingen and Stafford, Texas, that describes itself as the global leader in precision targeting of PRAME, an intracellular target that its TCR therapies can reach unlike classical antibodies and CAR T-cell therapies 1. The company has no product approved for sale and has funded operations mainly through equity financing and partner payments, raising 1.6 billion EUR cumulatively through December 31, 2025 1. Its strategy aims to become a fully integrated biopharmaceutical company that develops, manufactures and commercializes PRAME immunotherapies 1.
Research and development is focused on four initiatives: anzu-cel, IMA203CD8, IMA402 and unlocking strategic collaborations 1. Revenue comes solely from collaboration agreements, such as those with BMS and Moderna, not from product sales 1. Research and development expenses rose to 183,832 thousand EUR in fiscal 2025 from 148,079 thousand EUR in fiscal 2024, and accumulated losses of 786.0 million EUR at December 31, 2025 point to continued need for additional financing 1.
Near-term milestones include submitting a Biologics License Application for anzu-cel in the first half of 2027 and a data update from the SUPRAME phase 3 trial in 2026 1. If these steps proceed on schedule, anzu-cel could become the company's first PRAME product on the market 1.
Segments
Anzu-cel (IMA203), PRAME cell therapy
Anzu-cel is the lead product, a one-time infusion cell therapy for second-line or later advanced cutaneous melanoma and metastatic uveal melanoma; the confirmed response rate in the phase 1b trial is 56%, and the addressable population in the U.S. and EU5 includes about 9,000 patients 1.
IMA402, off-the-shelf bispecific
IMA402 is a half-life extended TCER bispecific with repeat dosing that could be used in earlier lines of treatment, including in combination with immune checkpoint inhibitors 1.
IMA203CD8 (GEN2)
IMA203CD8 is a second-generation PRAME cell therapy designed to extend treatment to multiple advanced solid cancers beyond melanoma, initially focusing on gynecologic cancers 1.
Market context
The company estimates the PRAME approach could address roughly 230,000 patients per year in the U.S. and EU5, and the first anzu-cel indications about 9,000 patients, of which about 4,300 are in the U.S. 1. The market for cell and bispecific immunotherapies in solid tumors is still at an early stage, and commercial access depends on regulatory approvals and clinical success 1.
Collaboration revenue fell to 48,266 thousand EUR in fiscal 2025 from 155,835 thousand EUR in fiscal 2024, reflecting lower payments from BMS and Moderna, which points to continued dependence on new milestones and partner payments 1.
Trends
- Growing interest in cell and bispecific therapies for cancertailwind
Therapies targeting intracellular proteins that classical antibodies cannot reach open a new therapeutic space for solid tumors 1.
- Complexity of patient-specific manufacturingheadwind
Cell therapies are manufactured individually for each patient, which raises costs and logistical challenges as programs move toward commercial stage 1.
- Dependence on partners and external fundingmixed
Revenue depends on collaborations and milestone-based payments, and additional capital could come with dilution or restrictive terms 1.
- Currency exposuremixed
The company reports in euros, and fluctuations against the U.S. dollar could affect results, given that a significant part of its activity is linked to the U.S. 1.
Competitive position
Immatics operates in a competitive field where other companies and therapeutic approaches, including tumor-infiltrating lymphocyte therapies and other cell therapies, could reach the market before or more successfully than its products 1.
The company's proposed differentiation rests on rapid manufacturing, single-infusion treatment and a favorable tolerability profile, but these clinical advantages still need to be confirmed in phase 3 studies 1.
- ModernaMRNA
Collaboration partner developing a PRAME cell therapy enhancer combined with anzu-cel, and also a potential competitor in messenger RNA-based therapies 1.
- Bristol Myers SquibbBMY
Collaboration partner that contributed to the company's revenue in earlier years and runs its own oncology immunotherapy programs 1.
- Genmab
Danish partner that contributed collaboration revenue in fiscal 2024 and is active in oncology therapies 1.
- Tumor-infiltrating lymphocyte therapy developers
Companies developing cell therapies based on tumor-infiltrating lymphocytes, which the company regards as an alternative approach for solid tumors 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual MeetingSurge — GDELT DOC · 24 Oct 2026 · RO
- Immatics and 4 More Stocks See Action From Activist InvestorsYahoo Finance — News · 04 Sept 2026 · EN
The latest news item in our archive is from 24 Oct 2026; the newest SEC filing is from 26 Oct 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Current report (foreign issuer)26 Oct 2026
- Current report (foreign issuer)23 Oct 2026
- Current report (foreign issuer)26 Aug 2026
- Current report (foreign issuer)18 Aug 2026
- Current report (foreign issuer)18 Jun 2026
- Current report (foreign issuer)02 Jun 2026
- Current report (foreign issuer)01 Jun 2026
- Current report (foreign issuer)12 May 2026
- Current report (foreign issuer)21 Apr 2026
- Current report (foreign issuer)17 Apr 2026
Sources
- [1] Form 20-F, fiscal year ended 2025-12-31 · SEC / Immatics N.V. · 05 Mar 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.